Schistosomiasis

Table of Contents

  1. Overview
  2. Epidemiology
  3. Life Cycle and Pathophysiology
  4. Acute Schistosomiasis (Katayama Fever)
  5. Chronic Intestinal/Hepatosplenic Schistosomiasis
  6. Urogenital Schistosomiasis
  7. Diagnosis
  8. Treatment
  9. Prevention
  10. Research and Advances
  11. References
  12. PubMed Searches
  13. Connections
  14. Featured Videos

Overview

Schistosomiasis — also known as bilharzia — is a chronic parasitic disease caused by flatworm trematodes of the genus Schistosoma. It ranks as the second most prevalent parasitic disease globally after malaria, with more than 200 million people currently infected and over 700 million at risk. The World Health Organization (WHO) classifies schistosomiasis as a neglected tropical disease (NTD), reflecting its devastating but largely invisible toll on the world's poorest communities.

Five species cause the vast majority of human disease. Schistosoma mansoni — found across sub-Saharan Africa, the Nile Delta, Brazil, and the Caribbean — causes intestinal and hepatic disease. Schistosoma haematobium — endemic in Africa and the Middle East — targets the urogenital system. Schistosoma japonicum — found in the Philippines, China, and Indonesia — causes hepatic and intestinal disease and is notably more pathogenic because it produces far more eggs per day than other species. Schistosoma mekongi (Mekong River basin) and Schistosoma intercalatum (central Africa) are geographically limited.

Unlike most other trematode (fluke) infections, adult schistosomes do not inhabit the gut or bile ducts. Instead, male and female worms live in intimate physical pairing within human blood vessels — specifically the portal and mesenteric veins (S. mansoni, S. japonicum) or the vesical venous plexus around the bladder (S. haematobium). This unusual habitat in the bloodstream allows continuous egg production over a worm lifespan of 5–10 years. The core pathology of schistosomiasis is not from the worms themselves but from the eggs: those that fail to exit the body lodge in host tissues, triggering a granulomatous immune response that drives progressive fibrosis and organ damage.

Back to Table of Contents

Epidemiology

Sub-Saharan Africa bears approximately 90% of the global schistosomiasis burden. S. mansoni is widespread around Lake Victoria, throughout the Nile Delta and East Africa, and in Brazil and the Caribbean. S. haematobium is the dominant species across most of sub-Saharan Africa and extends into the Middle East. S. japonicum is endemic in the Philippines, the Yangtze River basin in China, and parts of Indonesia.

The populations most affected are those with unavoidable occupational or domestic freshwater contact: school-age children who play and swim in lakes and rivers, farmers who wade through irrigation canals, and fishing communities who work in endemic water bodies. Poverty, lack of safe water supply, and absence of adequate sanitation perpetuate transmission cycles by ensuring that human excreta — containing schistosome eggs — contaminate freshwater sources continuously.

Unlike Leishmaniasis, malnutrition does not appear to be a direct driver of schistosomiasis susceptibility, though chronic infection itself causes significant nutritional deficits through anemia, protein-losing enteropathy, and growth stunting in children. The nutritional consequences of heavy chronic infection, particularly in school-age children, have major developmental and educational impacts.

Travelers are an increasingly recognized risk group. Numerous outbreaks of acute schistosomiasis have been documented among tourists — particularly those who swim in Lake Malawi, Lake Victoria, Lake Tanganyika, and similar freshwater bodies in sub-Saharan Africa. A single brief exposure in contaminated water is sufficient for infection; cercariae penetrate intact skin within minutes. Many travelers return home unaware of their exposure and present weeks later with febrile illness.

Back to Table of Contents

Life Cycle and Pathophysiology

The schistosome life cycle requires two hosts: a specific freshwater snail as an intermediate host and a mammal (usually humans) as the definitive host. Each Schistosoma species has a specific snail vector: Biomphalaria snails for S. mansoni, Bulinus snails for S. haematobium, and Oncomelania snails for S. japonicum.

In the snail: Schistosome eggs shed in human feces or urine hatch in freshwater, releasing free-swimming miracidia. Miracidia have only a few hours to locate and penetrate a compatible snail. Inside the snail, each miracidium undergoes asexual amplification through sporocyst stages, ultimately producing thousands of cercariae — free-swimming, fork-tailed larvae — which are released into the water over weeks to months.

Cercarial penetration: Cercariae swim actively and are attracted to water disturbance, light, and human skin secretions. They penetrate the skin directly — no cut or abrasion required — by secreting proteolytic enzymes that digest the outer layers. Penetration takes only minutes, and the forked tail is shed in the process. The resulting schistosomula migrate through the dermis into the subcutaneous circulation.

Migration and maturation: Schistosomula travel through the venous circulation to the lungs and then enter the systemic circulation, reaching the hepatic portal system within 1–2 weeks. In the liver, they mature into adult male and female worms over 4–6 weeks. The male worm's body forms a longitudinal groove (the gynecophoral canal) in which the slender female nestles permanently. This copulating pair migrates against portal blood flow to reach its target vessels: mesenteric veins for S. mansoni and S. japonicum, or the vesical venous plexus for S. haematobium.

Egg production and granuloma formation: Female worms begin laying eggs 5–7 weeks after initial infection. S. japonicum is the most prolific species, producing up to 3,000 eggs per day; S. mansoni produces 100–300 per day; S. haematobium produces 20–200 per day. Eggs are armed with a spine and secrete enzymes that help them traverse vessel walls and migrate through intestinal or bladder mucosa into the lumen, where they are shed. However, only about 50% of eggs successfully exit the body. The remainder are carried by portal blood into the liver, or embolize to the lungs, spinal cord, or brain.

Trapped eggs release antigens that trigger a host CD4+ T helper 2 (Th2) immune response, forming granulomas — aggregates of macrophages, eosinophils, and lymphocytes surrounding each egg. Acutely, granulomas serve a protective function by walling off toxic egg products. Chronically, repeated granuloma formation and resolution drives progressive collagen deposition and fibrosis, which is the principal cause of end-organ damage in schistosomiasis.

Back to Table of Contents

Acute Schistosomiasis (Katayama Fever)

Katayama fever is the syndrome of acute schistosomiasis, named after a region of Japan where early cases were described. It develops 2–8 weeks after a first heavy exposure in individuals with no prior immunity — most commonly travelers, migrants, and people encountering endemic water bodies for the first time. People with lifelong low-level re-exposure in endemic communities typically do not develop Katayama fever because they have acquired partial immunity.

The clinical syndrome is a serum sickness-like hypersensitivity reaction triggered by the migrating schistosomula and the onset of egg laying by newly matured female worms. It represents a massive immune complex-mediated inflammatory response rather than a direct effect of the parasites themselves. Characteristic features include:

The severity of Katayama fever correlates with the intensity of exposure. Most cases resolve spontaneously over weeks, but severe cases — particularly those with heavy exposure — can be life-threatening, with respiratory failure, encephalitis, or severe hepatic dysfunction. Diagnosis during Katayama fever is challenging because eggs are not yet present in stool or urine; diagnosis must rely on serology, which becomes positive 6–8 weeks after exposure.

Treatment: Praziquantel is the drug of choice, but it is less effective during Katayama fever because the drug acts primarily on adult worms, and migrating schistosomula are relatively resistant. For severe Katayama fever, corticosteroids (prednisolone 40 mg/day for 5 days, tapering) are used to suppress the immune-mediated inflammation. Praziquantel should be repeated at 4–6 weeks after initial treatment, when worms have fully matured, to ensure eradication.

Back to Table of Contents

Chronic Intestinal/Hepatosplenic Schistosomiasis

Chronic intestinal and hepatosplenic disease results from years of egg accumulation and granuloma formation in the liver and mesentery, primarily caused by S. mansoni and S. japonicum. The intestinal phase — bloody diarrhea, abdominal pain, and polyp formation in the bowel — is relatively minor and often overshadowed by the hepatosplenic manifestations.

Periportal (Symmer's pipe-stem) fibrosis: The pathognomonic lesion of hepatosplenic schistosomiasis is periportal fibrosis, first described by W. St. Clair Symmer in 1904. Eggs deposited in the portal tracts trigger granuloma formation and then replacement fibrosis. Unlike cirrhosis — where fibrosis is distributed throughout the hepatic lobule — schistosomal fibrosis is concentrated around the portal tracts. This produces the characteristic "pipe-stem" appearance on liver ultrasound: dense fibrotic sheaths surrounding portal vessels. The WHO has developed a standardized ultrasound classification system (Niamey protocol) widely used in field surveys to grade disease severity.

Portal hypertension: Progressive periportal fibrosis obliterates intrahepatic portal blood flow, driving portal hypertension. Clinical consequences include massive splenomegaly (the spleen may reach the pelvis), hypersplenism (thrombocytopenia, leukopenia), and formation of esophageal and gastric varices. Variceal hemorrhage — sudden, massive hematemesis — is a leading cause of death in endemic areas.

A clinically important distinction separates schistosomal hepatosplenic disease from cirrhosis: because the fibrosis is periportal rather than parenchymal, hepatocyte synthetic function is often surprisingly preserved until very late disease. Patients may present with massive splenomegaly, huge varices, and bleeding, yet have normal or near-normal serum bilirubin, albumin, and coagulation tests. This contrasts sharply with cirrhosis, where these markers are typically abnormal. This distinction has prognostic and management implications — patients with schistosomal portal hypertension have better liver functional reserve.

S. japonicum and neurological complications: Because S. japonicum produces far more eggs per day (up to 3,000) than S. mansoni or S. haematobium, it causes more severe hepatic disease and a higher rate of ectopic egg embolization. Eggs reaching the central nervous system produce cerebral and spinal granulomas, manifesting as seizures, focal neurological deficits, or transverse myelitis. Cerebral schistosomiasis is a recognized complication in S. japonicum-endemic areas in East Asia.

Back to Table of Contents

Urogenital Schistosomiasis

Urogenital schistosomiasis, caused by S. haematobium, is the most geographically prevalent form and affects an estimated 112 million people across sub-Saharan Africa and the Middle East. The bladder and ureters are the primary organs affected, but the disease extends to the female and male reproductive systems with profound consequences.

Hematuria: Painless terminal hematuria — blood appearing at the very end of the urinary stream — is the hallmark presenting symptom. It results from eggs penetrating the bladder mucosa into the urinary lumen. In highly endemic communities, hematuria in boys was historically considered a normal sign of male puberty (a "male menstruation"), leading to dramatic delays in seeking care. Urine dipstick testing for hematuria is used as a mass-screening surrogate for S. haematobium infection in field settings.

Obstructive uropathy: Chronic egg deposition in the bladder and ureter walls causes granuloma formation followed by fibrosis and calcification. Cystoscopy reveals characteristic "sandy patches" — yellowish granular lesions from dead, calcified eggs — and bladder wall thickening. Progressive ureteral fibrosis leads to stricture, hydroureter, and hydronephrosis. Bilateral obstructive uropathy can progress to renal failure, a significant cause of morbidity in heavily affected adults.

Bladder cancer: S. haematobium infection is classified by the International Agency for Research on Cancer (IARC) as a Group 1 definite human carcinogen. Chronic bladder inflammation and mucosal damage predispose to squamous cell carcinoma of the bladder — a tumor type distinct from the transitional cell carcinoma that predominates in Western countries. Schistosomiasis-associated bladder cancer tends to occur in younger individuals and is a major cause of cancer mortality in endemic regions of Egypt and East Africa.

Female genital schistosomiasis (FGS): Eggs deposited in the vulva, vagina, cervix, uterus, and fallopian tubes cause a chronic inflammatory condition known as female genital schistosomiasis, affecting an estimated 40 million women. FGS produces grainy sandy patches and abnormal blood vessels on the cervix and vaginal mucosa — lesions that disrupt the epithelial barrier and have been shown to increase susceptibility to HIV infection by 3–4 fold. FGS also causes infertility, dyspareunia, ectopic pregnancy, and obstetric complications. Because FGS lesions closely resemble sexually transmitted infection findings on pelvic examination, it is frequently misdiagnosed and undertreated.

Male genital schistosomiasis: Eggs can also deposit in the seminal vesicles, prostate, epididymis, and testes. Male genital schistosomiasis presents as orchitis, epididymitis, hematospermia, or chronic pelvic pain. As with FGS, it is frequently misattributed to other causes.

Back to Table of Contents

Diagnosis

Diagnosis of schistosomiasis combines parasitological identification of eggs, serological testing, imaging, and clinical evaluation. The appropriate approach depends on the clinical setting, disease phase, and available resources.

Stool microscopy (Kato-Katz thick smear): The WHO-recommended field gold standard for intestinal schistosomiasis. A standardized 41.7 mg stool sample is pressed through a template and examined microscopically for characteristic eggs. S. mansoni eggs are oval with a lateral spine; S. japonicum eggs are smaller and round with a rudimentary lateral spine; S. intercalatum eggs have a terminal spine. Sensitivity depends on infection intensity — a single smear may miss light infections, so at least two samples collected on separate days is recommended. Kato-Katz is inexpensive and practical for high-burden settings.

Urine filtration for S. haematobium: A midday urine sample (10–10 AM – 2 PM, when egg shedding peaks) is passed through a nucleopore polycarbonate membrane filter and examined for eggs with terminal spines. Multiple samples improve sensitivity.

Serology: ELISA and immunoblot assays detect anti-schistosome antibodies, becoming positive 6–8 weeks after infection. Serology is particularly valuable for diagnosing Katayama fever (when eggs are not yet present) and for diagnosing light infections in travelers returning from endemic areas. Cross-reactivity with other helminth infections limits specificity in some contexts.

Urine dipstick for hematuria: In high-burden S. haematobium communities, urine dipstick testing for blood is used as an inexpensive, low-resource screening tool. It is not diagnostic but identifies individuals who need further evaluation or empiric treatment.

Rectal snip biopsy: A small biopsy of rectal mucosa pressed between glass slides and examined microscopically can reveal eggs — particularly useful for diagnosing chronic light-burden infections in individuals with negative stool smears.

PCR: Highly sensitive molecular detection of schistosome DNA in stool, urine, or serum. PCR is superior to microscopy for light infections and can distinguish species, but is not yet widely available in endemic settings. Real-time PCR is increasingly used in reference laboratories for travelers and for monitoring treatment response in clinical trials.

Ultrasound: Abdominal ultrasound is the definitive imaging modality for hepatosplenic schistosomiasis. The WHO Niamey protocol provides a standardized scoring system for portal fibrosis severity based on echogenicity of portal tracts, portal vein diameter, presence of portosystemic collaterals, and spleen size. Ultrasound is excellent for field surveys in endemic communities and for monitoring disease progression.

Cystoscopy: Reveals the characteristic sandy patches of bladder schistosomiasis — yellowish granular lesions — as well as bladder wall thickening, pseudo-polypoid lesions, and fibrosis. Essential for evaluating bladder cancer risk.

Laboratory findings: Peripheral eosinophilia is characteristic during early and active infection. Chronic heavy infection with hypersplenism causes pancytopenia — thrombocytopenia, anemia, and leukopenia. Elevated liver enzymes reflect ongoing hepatic granuloma formation; in late hepatosplenic disease, markers of synthetic function may remain surprisingly normal despite advanced fibrosis.

Back to Table of Contents

Treatment

Praziquantel (PZQ) is the cornerstone of schistosomiasis treatment and has been so since the 1970s. It is effective, orally administered, inexpensive, and generally well tolerated — making it suitable for mass treatment programs.

Dosing:

Mechanism and limitations: Praziquantel acts by increasing calcium permeability of the worm's tegument, causing muscular spasm and tegumental disruption, which exposes worm antigens to the host immune system. It kills adult worms effectively but has minimal activity against migrating schistosomula (early larval stages) and newly penetrated cercariae. This is a critical limitation: PZQ given during the first 4–6 weeks after exposure — before worms mature — will not eliminate the infection. For Katayama fever, praziquantel may have limited initial efficacy, and a second dose at 4–6 weeks after the first (once worms have fully matured) is essential.

Important clinical point: Praziquantel treats the living worm burden but does not reverse established fibrosis. Patients with Symmer's pipe-stem fibrosis and portal hypertension who are treated with PZQ will stop accumulating further damage but will not regress already-formed fibrosis. Management of complications (variceal banding or shunting, splenectomy for hypersplenism) may still be required.

Side effects: Generally mild and transient — abdominal pain, nausea, headache, and dizziness — often attributable to dying worms rather than direct drug toxicity.

Mass drug administration (MDA): The WHO strategy for schistosomiasis control targets annual or biannual PZQ treatment to school-age children (and sometimes the entire adult population) in high-burden areas. MDA reduces worm burden and morbidity substantially at the population level, even if it does not eliminate infection. Preventive chemotherapy programs have been scaled up dramatically since 2000 through partnerships with the Schistosomiasis Control Initiative (SCI) and donated drug programs.

Oxamniquine: An alternative agent active only against S. mansoni, historically used in Brazil and parts of Africa. No longer widely available and not recommended as first-line treatment given the availability and broader spectrum of praziquantel.

Artemisinins: Artemisinin derivatives (the antimalarial drugs) show activity against early schistosomula in animal models and have been studied for prophylaxis in travelers and in early post-exposure treatment. Early human data suggest some protective effect when given within the first few weeks of exposure, but their role in standard treatment guidelines has not yet been established.

Monitoring: Follow-up stool or urine examination 4–6 weeks after treatment confirms egg clearance and treatment success. Persistent egg-positive results at 6 weeks indicate treatment failure and warrant a repeat course.

Emerging resistance: Praziquantel resistance has been reported in laboratory-selected strains and in a small number of clinical failures, but is not yet a widespread clinical problem. Given that PZQ is the sole first-line agent for all schistosome species, resistance development would be a serious public health threat — making pipeline drug development a priority.

Back to Table of Contents

Prevention

Prevention of schistosomiasis requires a multi-pronged approach because no vaccine is yet available for human use, and no chemoprophylactic drug is reliably effective for prevention.

Avoiding freshwater contact: The most effective individual prevention measure is avoiding wading, swimming, or bathing in freshwater lakes, rivers, ponds, or irrigation canals in endemic areas. This is especially critical in sub-Saharan Africa — Lake Malawi, Lake Victoria, and Lake Tanganyika are well-documented sites of tourist exposure. Even brief contact (a few minutes) is sufficient for cercarial penetration.

Water treatment: Cercariae are killed by heating water to 50°C for 5 minutes before use. Water can also be treated with iodine or chlorine (at standard water-purification doses). Allowing water to stand undisturbed for more than 48 hours allows cercariae to die naturally. These methods are practical for drinking and bathing water but do not address environmental exposure.

Topical measures: No topical repellent has proven reliably effective at preventing cercarial skin penetration. Vigorous toweling after accidental water exposure may mechanically remove some cercariae before full penetration, but this is of limited and uncertain benefit.

Snail control: Niclosamide, a molluscicide, can be applied to bodies of water to reduce snail populations and thus cercarial release. However, ecological concerns, the cost of large-scale application, and the rapid recolonization of treated water bodies limit the long-term effectiveness of mollusciciding as a standalone strategy.

Safe water and sanitation (WASH): Preventing the contamination of freshwater with human feces and urine — through access to toilets, safe water supplies, and handwashing — interrupts the transmission cycle at its source. WASH infrastructure improvements are essential for sustainable elimination of schistosomiasis but require substantial long-term investment.

Health education: Community education programs that inform populations about the transmission cycle, the role of freshwater contact, and the availability of treatment are integral to control programs. Correct understanding of why children should not swim in endemic water bodies can reduce exposure substantially.

WHO preventive chemotherapy (MDA): Annual or biannual mass administration of praziquantel to school-age children — and in high-burden settings to all adults at risk — is the WHO's primary strategy for morbidity control. MDA programs do not eliminate transmission but dramatically reduce the heavy worm burdens responsible for organ damage, growth stunting, and anemia.

Traveler guidance: Travelers to sub-Saharan Africa should avoid all freshwater contact outside of chlorinated pools. Any traveler who has had freshwater exposure in an endemic area should be evaluated for schistosomiasis by serology 6–8 weeks after potential exposure, even in the absence of symptoms. Post-exposure serological screening is recommended for travelers returning from Lake Malawi, Lake Victoria, and other high-risk sites.

Back to Table of Contents

Research and Advances

Schistosomiasis research has accelerated significantly in the 21st century, driven by genomic advances, global health investment, and the urgent need for new tools beyond praziquantel.

Vaccine development: The Sm-p80 antigen derived from the large subunit of the S. mansoni calpain protein has emerged as the most advanced vaccine candidate. It has demonstrated dose-dependent protection in baboon and mouse models, with reductions in adult worm burden and egg production exceeding 90% in some studies. Sm-p80 has completed Phase 1 safety trials and entered Phase 2 efficacy trials in Zambia. The WHO has set a target of a licensed schistosomiasis vaccine by 2030. Other candidates include Sm-TSP-2 (tetraspanin) and Sh28GST (a glutathione S-transferase), the latter being in advanced clinical development as Bilhvax.

Pediatric praziquantel: Standard praziquantel tablets are large, bitter, and difficult for young children to swallow. The Pediatric Praziquantel Consortium — a public-private partnership — has developed an age-appropriate, dispersible tablet formulation suitable for children under 6 years of age, a population currently excluded from MDA programs despite high infection rates. Phase 3 trials of the new formulation are complete and regulatory approval is anticipated.

Point-of-care diagnostics: Detection of circulating cathodic antigen (CCA) and circulating anodic antigen (CAA) in urine or serum offers highly sensitive, non-microscopic diagnosis. CAA detection in particular is exquisitely sensitive, able to detect single-worm infections. Lateral flow CCA tests are already in field use; more sensitive CAA tests are in development. These tools are transforming the ability to diagnose low-burden infections and to accurately assess treatment success after MDA.

Genomics and drug targets: The complete genomes of S. mansoni, S. haematobium, and S. japonicum have been sequenced and annotated. Comparative genomics has identified parasite-specific proteins — histone deacetylases, kinases, and tegumental surface proteins — as potential drug targets. High-throughput screening of compound libraries against schistosome drug targets is generating new lead compounds.

Understanding fibrosis mechanisms: Regulatory T cells (Tregs) and IL-13 signaling play central roles in driving the Th2 response that produces fibrosis. Understanding how to modulate this response — suppressing fibrosis without eliminating protective granuloma formation — is an active area of immunological research with implications for treatment of established fibrotic disease.

Water treatment technology: Ozone treatment and ultraviolet light have been shown to inactivate cercariae in water treatment applications. Integration of these technologies into community water supplies in endemic areas could interrupt transmission at the environmental level, complementing drug-based control strategies.

Back to Table of Contents

References

  1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet. 2006;368:1106–1118. DOI: 10.1016/S0140-6736(06)69440-3 — PMID 16997665
  2. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet. 2014;383:2253–2264. DOI: 10.1016/S0140-6736(13)61949-2 — PMID 24698483
  3. Hotez PJ, Alvarado M, Basáñez MG, et al. The neglected tropical diseases: overview as a cause of death. PLoS Negl Trop Dis. 2014;8:e3025. DOI: 10.1371/journal.pntd.0003025 — PMID 25121853
  4. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helminthic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet. 2005;365:1561–1569. DOI: 10.1371/journal.pntd.0000002 — PMID 16556170
  5. Richter J, Hatz C, Häussinger D. Ultrasound in tropical and parasitic diseases. Acta Trop. 2003;86:135–141. DOI: 10.1016/s0001-706x(03)00032-3 — PMID 12745148
  6. Lamberton PHL, Webster JP. The contribution of genetically modified organisms to schistosomiasis control. Trends Parasitol. 2018;34:671–682. DOI: 10.1016/j.pt.2018.05.004 — PMID 29804641
  7. Picquet M, Ernould JC, Vercruysse J, et al. Schistosomiasis morbidity and infection levels in school-aged children in the Senegal River basin. Trans R Soc Trop Med Hyg. 1996;90:187–190. DOI: 10.1016/s0035-9203(96)90131-6 — PMID 8758075
  8. Kabatereine NB, Brooker S, Tukahebwa EM, Kazibwe F, Onapa AW. Epidemiology and performance of a rapid diagnostic test for Schistosoma mansoni infection. Trans R Soc Trop Med Hyg. 2004;98:470–475. DOI: 10.1016/j.trstmh.2004.02.001 — PMID 15363641
  9. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections. JAMA. 2008;299:1937–1948. DOI: 10.1001/jama.299.16.1937 — PMID 18430913
  10. Fenwick A, Webster JP, Bosque-Oliva E, et al. The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology. 2009;136:1719–1730. DOI: 10.1016/S0065-308X(05)61014-7 — PMID 16735172
  11. McManus DP, Dunne DW, Sacko M, Utzinger J, Vennervald BJ, Zhou XN. Schistosomiasis. Nat Rev Dis Primers. 2018;4:13. DOI: 10.1038/s41572-018-0013-8 — PMID 29924119
  12. Lo NC, Addiss DG, Hotez PJ, et al. A research agenda for helminth diseases of humans: intervention for control and elimination. PLoS Negl Trop Dis. 2018;12:e0006769. DOI: 10.1371/journal.pntd.0006769 — PMID 30212455

Back to Table of Contents

PubMed Searches

The following PubMed search links provide access to the latest peer-reviewed research on schistosomiasis:

  1. Schistosomiasis treatment with praziquantel
  2. Hepatosplenic schistosomiasis and portal hypertension
  3. S. haematobium urogenital disease and bladder cancer
  4. Katayama fever acute schistosomiasis
  5. Female genital schistosomiasis and HIV susceptibility
  6. Schistosomiasis vaccine Sm-p80 clinical trial
  7. Schistosomiasis diagnosis circulating cathodic antigen
  8. Schistosomiasis mass drug administration in school children

Back to Table of Contents

Connections

Back to Table of Contents